MIRANDA
Research type
Research Study
Full title
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (MIRANDA)
IRAS ID
1008401
Contact name
Krishna Varsani
Contact email
Sponsor organisation
AstraZeneca AB
Eudract number
2023-505543-39
Research summary
This study tests whether a new medication called “tozorakimab” is safe and works in people with chronic obstructive pulmonary disease (COPD) with a history of COPD exacerbations. Researchers are looking for a better way to treat people with chronic obstructive pulmonary disease (COPD) who have a history of COPD exacerbations. COPD is a long-term condition caused by damaging and narrowing the airways. This can lead to difficulty breathing, coughing, and phlegm. COPD exacerbations are when a person’s symptoms worsen, also known as a “flare-up.” The medication being tested, tozorakimab, was designed to stop a protein called interleukin-33 (IL-33) from activating one of the immune system pathways. The researchers think that this could reduce inflammation and other COPD symptoms. The scientists want to know if tozorakimab is safe and works in people with COPD by reducing and preventing the exacerbations compared to a placebo. The placebo in this trial looks like tozorakimab but lacks tozorakimab. All participants will continue taking their standard COPD treatments during the trial.
REC name
Wales REC 3
REC reference
23/WA/0321
Date of REC Opinion
7 Dec 2023
REC opinion
Further Information Favourable Opinion